Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing

References

• Guilhot F, on behalf of the IRIS Study Group. Sustained durability of responses plus high rate of cytogenetic responses result in long-term benefit for newly diagnosed chronic-phase chronic myeloid leukemia treated with imatinib therapy: update from the IRIS study. Blood 2004; 104: 10a
   Web of Science ®Google Scholar
• Hochhaus A, Kreil S, Corbin A S, La Rosée P, Muller M C, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196
   PubMed Web of Science ®Google Scholar
• O'Brien S G, Guilhot F, Larson R A, Gathmann I, Baccarani M, Carvantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Eng J Med 2003; 348: 994–1004
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Cortes J E, O'Brien S, Luthra R, Giles F, Verstovsek S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-α. Blood 2004; 104: 1979–1988
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver R T, Druker B J, Goldman J M, Gambacorti-Passerini C, Guilhot F, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928–1937
   PubMed Web of Science ®Google Scholar
• Sawyers C L, Hochhaus A, Feldman E, Goldman J M, Miller C B, Ottmann O G. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539
   PubMed Web of Science ®Google Scholar
• Sumi M, Tauchi T, Shimamoto T, Sshida G, Nakajima A, Ito Y, et al. Chronic myeloid leukemia associated with sustained severe pancytopenia after imatinib mesylate therapy. Rinsho Ketsueki 2002; 43: 868–870
   PubMedGoogle Scholar
• Quintas-Cardama A, Kantarjian H, O'Brien S, Garcia-Manero G, Rios M B, Talpaz M, et al. Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia. Cancer 2004; 100: 2592–2597
   PubMed Web of Science ®Google Scholar
• Marin D, Marktel S, Foot N, Bua M, Goldman J M, Apperley J F. Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica 2003; 88: 227–229
   PubMed Web of Science ®Google Scholar
• Sokal J E, Cox E B, Baccarani M, Tura S, Gomez G A, Robertson J E, et al. Prognostic discrimination in ‘good-risk’ chronic granulocytic leukemia. Blood 1984; 63: 789–799
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, Allan N C, Baccarani M, Kluin-Nelemans J C, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. J Nat Cancer Inst 1998; 90: 850–858
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group on chronic myeloid leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Eng J Med 1994; 330: 820–825
   PubMed Web of Science ®Google Scholar
• Chomczynski P, Sacchi N. Single-step method of RNA isolation by quanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156–159
   PubMed Web of Science ®Google Scholar
• Gabert J, Beillard E, van der Velden V HJ, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for rezidual disease detection in leukemia—a Europe against cancer program. Leukemia 2003; 17: 2318–2357
   PubMed Web of Science ®Google Scholar
• Parise R A, Ramanathan R K, Hayes M J, Egorin M J. A sensitive high-performance liquid chromatography-mass spectrometry assay for quantitation of imatinib and it's main metabolite (CGP 74588) in plasma. J Chromatol B 2003; 791: 39–44
   PubMed Web of Science ®Google Scholar
• Yeh K C, Kwan K C. A comparison of numerical integrating algorithms by trapezoidal, Lagrange, and spline approximation. J Pharmacokinetics Biopharm 1978; 6: 79–98
   PubMedGoogle Scholar
• Rocci M L, Jr, Jusko W J. LAGRAN program in area and moments in pharmacokinetic analysis. Comput Programs Biomed 1983; 16: 203–216
   PubMedGoogle Scholar
• Peng B, Hayes M, Resta D, Racine-Poon A, Druker B J, Talpaz M, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol 2004; 22: 935–942
   PubMed Web of Science ®Google Scholar
• Horikoshi A, Takei K, Sawada S. Effects of lower dose of imatinib to CML patients. Leuk Res 2003; 27: 1167
   PubMed Web of Science ®Google Scholar
• Tanvetyanon T, Nand S. Overcoming recurrent cutaneous reactions from imatinib use by once-weekly dosing. Ann Pharmacother 2003; 37: 1818–1820
   PubMed Web of Science ®Google Scholar
• Zipin D, Savage D G. Reduced dose imatinib mesylate therapy for chronic myeloid leukemia. Leuk Lymphoma 2004; 45: 2363–2364
   PubMed Web of Science ®Google Scholar
• Cortes J, Giles F, O'Brien S, Thomas D, Garcia-Manero G, Beth Rios M, et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-α. Blood 2003; 102: 83–86
   PubMed Web of Science ®Google Scholar
• Cortes J, O'Brien S, Kantarjian H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 2004; 104: 2204–2205
   PubMed Web of Science ®Google Scholar
• Hochhaus A, La Rosée P. Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia 2004; 18: 1321–1331
   PubMed Web of Science ®Google Scholar
• Liu N S, O'Brien S. Spontaneous reversion from blast to chronic phase after withdrawal of imatinib mesylate in a patient with chronic myelogenous leukemia. Leuk Lymphoma 2002; 43: 2413–2415
   PubMed Web of Science ®Google Scholar
• Higashi T, Tsukada J, Kato C, Iwashige A, Mizobe T, Machida S, et al. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. Am J Hematol 2004; 76: 275–278
   PubMed Web of Science ®Google Scholar
• Murase K, Matsunaga T, Takeuchi N, Fujimi A, Takimoto R, Terui T, et al. Second hematologic response and disappearance of the ABL gene mutant clone by cessation of imatinib in a CML patient with resistance to imatinib. Rinsho Ketsueki 2004; 45: 1028–1032
   PubMedGoogle Scholar
• Desplat V, Belloc F, Lagarde V, Boyer C, Melo J V, Reiffers J, et al. Overproduction of BCR-ABL induces apoptosis in imatinib mesylate-resistant cell lines. Cancer 2005; 103: 102–110
   PubMed Web of Science ®Google Scholar
• Sneed T B, Kantarjian H M, Talpaz M, O'Brien S, Rios M B, Bekele B N. The significance of myelosupression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004; 100: 116–121
   PubMed Web of Science ®Google Scholar
• Wang J Y. Regulation of cell death by the Abl tyrosine kinase. Oncogene 2000; 19: 5643–5650
   PubMedGoogle Scholar